Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

Alfonso Quintas-Cardama, Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, Guillermo Garcia-Manero, Srdan Verstovsek, Mary Beth Rios, Kimberly Hayes, Armand Glassman, B. Nebiyou Bekele, Xian Zhou, Jorge Cortes

Research output: Contribution to journalArticle

93 Scopus citations

Fingerprint Dive into the research topics of 'Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds